Concepedia

Publication | Open Access

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study

DOIFull Paper Access

56

Citations

12

References

2021

Year

Maureen M. Jonas, Susan Rhee, Déirdre Kelly, Antonio Del Valle‐Segarra, Cornelia Feiterna‐Sperling, Susan Gilmour, Regino P. González‐Peralta, Loreto Hierro, Daniel H. Leung, Simon C. Ling,
Hepatology

Abstract

A pediatric formulation of GLE/PIB was highly efficacious and well tolerated in chronic HCV-infected children 3 to < 12 years old.

References

YearCitations

Page 1